Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Steatitis”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

84 records · Page 5Linked to original sources
PubMed1980

[Hepatic and intestinal toxicity of furazan and furoxan derivatives].

Histological examination revealed that 4-methylfurazan-3-carboxylic acid hydrazide (I); 3-methylfuroxan-4-carboxylic acid hydrazide (II); 4-methylfurazan-3-carboxylic acid amide(III); 4-methylfuroxan-3-carboxylic acid amide (IV), caused hepatic and intestinal lesion in the mouse. At the higher doses a destruction of the intestinal mucosa and a vasodilatation of the hepatic sinusoid was observed. At lower doses hepatic steatosis was observed.

Animals↗
PubMed1975

[An attempt at correlation between the numbers of intra-hepatic immunocytes and levels of serum immunoglobulins during the course of various liver diseases].

Liver samples from 71 patients with various liver diseases were obtained by needle-biopsy and examined by the direct fluorescent antibody technique. Immunocytes reacting with specific conjugated anti-IgG, A, M sera were counted. An attempt to correlate i-munocytochemical observations with Ig-levels was performed but remained statistically non valid. Nevertheless, graphic comparison of data in the three homogeneous investigated groups (steatosis, cirrhosis, hepatitis) might support the view that intra-hepatic immunocytes contribute partially to enhance the serum immunoglobulin levels in liver diseases.

Animals↗
PubMed1993

Pharmacological studies on taurohyodeoxycholic acid.

In this study we investigated the anticholelithogenic and choleretic activities and the general pharmacological action of taurohyodeoxycholic acid (THDCA, Io, Praxis, CAS 2958-04-5), a new biliary acid advocated for use as anticholelithogenic agent. THDCA had no significant activity on the CNS (spontaneous locomotor activity, body temperature, coordinated movement, respiration); it also had no significant anticonvulsant or central anticholinergic actions. With regard to the action on the cardiovascular system, THDCA administration did not give rise to significant changes in blood pressure or ECG. Investigation of its action on the gastrointestinal system revealed no significant changes in the intestinal transport of charcoal after treatment. However, biliary flow and biliary solids content were increased by THDCA intraduodenal doses of 300 mg/kg b.w. In mice fed with lithogenic diet THDCA administration (230 and 450 mg/kg b.w. for 8 weeks) significantly decreased gallstone and steatosis incidence.

Animals↗